关键词: C反应蛋白, 血清铁参数, 重组人促红细胞生成素, 肾性贫血

Abstract: Objective　To investigate the clinical application significance of combining determination of C reactive protein （CRP） and serum iron parameters for the recombinant human erythropoietin (rHuEPO) treatment of renal anemia(RA). Methods　All 75 patients with RA were classified intoⅠ(CRP>8 mg/L, 37 patients) and Ⅱ(CRP≤8 mg/L, 38 patients) groups， and administrated rHuEPO at dose of 80120 U/kg for a week(2 times). Before the treatment， red cell indices［red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT) and reticulocyte counting percentage (RET%)］， iron metabolism parameters［serum transferrin receptor(sTfR), serum iron (SI), transferrin saturation (TS%) and serum ferritin (SF)］ and CRP were measured. The iron metabolism parameters after the treatment 8 weeks and red cell indices after 2，4 and 8 weeks were measured, and the results were analyzed statistically. Results　The 2 groups′ sTfR and CRP before the treatment were different statistically（P<0.05）. After the treatment， red cell indices and sTfR in groupⅡ increased, and SF decreased. Compared with before treatment group and after treatment groupⅠ， there were significant differences （P<0.05）. There was negative correlation between CRP and Hb（r=-0.55，P<0.01）， and positive correlation between CRP and SF（r=0.65，P<0.01） in groupⅠ. In groupⅡ, sTfR and Hb were positively correlated （r=0.71，P<0.01）, and sTfR and SF were negatively correlated （r=-0.48，P<0.05）. Conclusions　CRP combined with serum iron parameters can guide the application of rHuEPO, and has clinical significance in evaluating and predicting the effect of rHuEPO in the treatment of renal anemia.

Key words: C reactive protein, Serum iron parameter, Recombinant human erythropoietin, Renal anemia